|
Monday, 08/02/2010
|
Longitudinal Methods for Analysis of Tumor Burden Data
Ritwik Sinha, Bristol-Myers Squibb; Aparna B. Anderson, Bristol-Myers Squibb
|
A Multistate Modeling and Prediction of Survival Distribution Using Information on Subject's Tumor Response Over Time
Shengyan Hong, MedImmune; Iiya Lipkovich, Eli Lilly and Company; Yan Daniel Zhao, Eli Lilly and Company
9:50 AM
|
A Bayesian Model for Misclassified Binary Outcomes and Correlated Survival Data, with Applications to Breast Cancer
Min Yi, The University of Texas Health Science Center at Houston; Sheng Luo, The University of Texas School of Public Health; Xuelin Huang, MD Anderson Cancer Center; Kelly K. Hunt, MD Anderson Cancer Center
11:15 AM
|
Semiparametric Regression Inference for Tumor Progression in Cancer Studies
Chen Hu, University of Michigan; Alexander Tsodikov, University of Michigan
11:20 AM
|
Semiparametric Bayesian Analysis of High-Throughput Array CGH Data
Subharup Guha, University of Missouri
2:35 PM
|
|
Tuesday, 08/03/2010
|
High Dimentional ROC Analysis Can Improve the Correlation Between Histological Grade (HG) and Oncotype-Dx (ONC) Recurrence Risk (RR) in Breast Cancer (BC)
Yufeng Li, The University of Alabama at Birmingham; Choo Hyung Lee, The University of Alabama at Birmingham; Omar Hameed, The University of Alabama at Birmingham
|
The Data Dependence in Modeling Rat's Tumor Growth Data
Chong Yau Fu, National Yang Ming University; Yueh-Hsing Ou, Institute of Bioonology in Medicine; Shih-Hua Liu, National Yunlin University of Science and Technology
|
Hierarchical Weakest-Link Models in Cytometry of Lung Tumor Samples
The Minh Luong, University of Pittsburgh; Roger Day, University of Pittsburgh
|
A Hybrid Geometric Select-and-Test Design Based on Treatment Failure Time and Toxicity
Peter F. Thall, MD Anderson Cancer Center
2:05 PM
|
|
Wednesday, 08/04/2010
|
Assessing the Impact of Tumor Heterogeneity on Powering Microarray Signature Discovery
Timothy Scott Davison, Almac Diagnostics; Sian Dibben, Almac Diagnostics; Janet Taylor, Almac Diagnostics; Robert J. Holt, Almac Diagnostics; Paul J. Kelly, Belfast Health and Social Care Trust; Ian Paul, Queen's University Belfast; Peter Kerr, Almac Diagnostics; Dean A. Fennell, Queen's University Belfast; Jacqueline A. James, Queen's University Belfast; Richard D. Kennedy, Almac Diagnostics
|
Bayesian Adaptive Phase II/III Clinical Trial Design Using the Relationship Between Tumor Response and Survival
Donald Arthur Berry, MD Anderson Cancer Center; Haiying Pang, MD Anderson Cancer Center
9:20 AM
|
Testing Clonality of Three and More Tumors Using Their Loss of Heterozygosity Profiles
Irina Ostrovnaya, Memorial Sloan-Kettering Cancer Center; Colin Begg, Memorial Sloan-Kettering Cancer Center
11:05 AM
|
|